Currently, there are 115.76M common shares owned by the public and among those 99.22M shares have been available to trade.
The company’s stock has a 5-day price change of 12.15% and -8.02% over the past three months. ARQT shares are trading 222.91% year to date (YTD), with the 12-month market performance up to 12.15% higher. It has a 12-month low price of $1.76 and touched a high of $13.17 over the same period. ARQT has an average intraday trading volume of 2.98 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.51%, 20.78%, and 62.12% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) shares accounts for 98.62% of the company’s 115.76M shares outstanding.
It has a market capitalization of $1.21B and a beta (3y monthly) value of 1.18. The earnings-per-share (ttm) stands at -$2.92. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.82% over the week and 8.43% over the month.
Earnings per share for the fiscal year are expected to increase by 55.07%, and 27.09% over the next financial year. EPS should grow at an annualized rate of 9.80% over the next five years, compared to -48.07% over the past 5-year period.
Looking at the support for the ARQT, a number of firms have released research notes about the stock. Mizuho stated their Buy rating for the stock in a research note on January 03, 2024, with the firm’s price target at $4-$8. Mizuho coverage for the Arcutis Biotherapeutics Inc (ARQT) stock in a research note released on October 26, 2023 offered a Neutral rating with a price target of $4. Goldman was of a view on October 13, 2023 that the stock is Neutral, while Needham gave the stock Buy rating on September 07, 2022, issuing a price target of $46. Goldman on their part issued Buy rating on March 17, 2022.
